Tissue Transglutaminase Appears In Monocytes And Macrophages But Not In Lymphocytes In White Matter Multiple Sclerosis Lesions

Leukocyte infiltration is an important pathological hallmark of multiple sclerosis (MS) and is therefore targeted by current MS therapies. The enzyme tissue transglutaminase (TG2) contributes to monocyte/macrophage migration and is present in MS lesions and could be a potential therapeutic target. We examined the cellular identity of TG2-expressing cells by immunohistochemistry in white matter lesions of 13 MS patients; 9 active and chronic active lesions from 4 patients were analyzed in detail. In these active MS lesions, TG2 is predominantly expressed in leukocytes (CD45(+)) but not in cells of the lymphocyte lineage, that is, T cells (CD3(+)) and B cells (CD20(+)). In general, cells of the monocyte/macrophage lineage (CD11b(+) or CD68(+)) are TG2(+) but no further distinction could be made regarding pro-or anti-inflammatory macrophage subtypes. In conclusion, TG2 is abundantly present in cells of the monocyte/macrophage lineage in active white matter MS lesions. We consider that TG2 can play a role in MS as it is associated with macrophage infiltration into the CNS. As such, TG2 potentially presents a novel target for therapeutic intervention that can support available MS therapies targeting lymphocyte infiltration.